Nuvilex Inc (NVLX) 0.1800 $NVLX
Nuvilex targeted chemo an Orphan Drug for pancreatic cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:02AM CST
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment
GlobeNewswire - Mon Dec 22, 7:40AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex's pancreatic cancer treatment combines Nuvilex's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials.
Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation in New Facility
GlobeNewswire - Thu Dec 18, 11:56AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova's new facility in the Thai Science Park in Bangkok, Thailand. This is an important milestone in assuring the facility is compliant with the current Good Manufacturing Practices (cGMP) and that the encapsulation of the cancer prodrug-activating cells used in the Cell-in-a-Box technology platform, as part of Nuvilex's pancreatic cancer treatment, will be fully functional.
Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs
GlobeNewswire - Tue Dec 16, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box cellulose-based live cell encapsulation technology.
Nuvilex Provides Update on Significance of Austrianova's cGMP Live-Cell Encapsulation Facility
GlobeNewswire - Wed Dec 10, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park (TSP). This facility will produce the Cell-in-a-Box live-cell encapsulation product that will be the centerpiece for all of Nuvilex's treatments in human clinical trials.
Nuvilex Announces Name Change of Subsidiary to Viridis Biotech
GlobeNewswire - Mon Dec 08, 9:15AM CST
Nuvilex, Inc. (OTCQB:NVLX), a preclinical and clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has changed the name of its subsidiary, Medical Marijuana Sciences, Inc., to Viridis Biotech, Inc. This name change is part of Nuvilex's continuing process to make changes at Nuvilex that better reflect its role as a biotechnology company and to strengthen the Nuvilex brand.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Nuvilex Announces the Opening of Austrianova's cGMP Live Cell Encapsulation Facility in Thailand
GlobeNewswire - Thu Dec 04, 8:44AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova's current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.
Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine
GlobeNewswire - Mon Dec 01, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has obtained an exclusive worldwide license from Austrianova Singapore Pte Ltd to use the unique and proprietary Cell-in-a-Box cellulose-based live cell encapsulation technology in combination with compounds, known as cannabinoids, obtained from constituents of Cannabis for the development of disease treatments. Nuvilex's initial efforts will be directed toward developing treatments for deadly and difficult-to-treat forms of cancer.
Legal Marijuana Industry Outlook Positive As Advanced Technologies & Socially Acceptable Cannabis Products Lead to Increased Revenues
PR Newswire - Mon Nov 24, 9:57AM CST
Legal Marijuana & Cannabis Industry lean more toward heavily capitalized investors as Leading Technology & MMJ Manufacturers set sights on the Mainstream and becoming more socially acceptable. Major MMJ Companies in focus today are: Surna Inc. (OTC: SRNA), Medical Marijuana Inc. (OTC: MJNA), Hemp, Inc. (OTC: HEMP), Cannabis Science, Inc. (OTC: CBIS) and Nuvilex, Inc. (OTC: NVLX)
Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes
GlobeNewswire - Mon Nov 24, 7:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a "Diabetes Consortium" that will be tasked with the development of Nuvilex's treatment for insulin-dependent diabetes.
Nuvilex Executives in Southeast Asia to Further Advance Cell-in-a-Box Technology(R)
GlobeNewswire - Fri Nov 21, 8:36AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today Nuvilex's Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will develop a treatment for insulin dependent diabetes, to negotiate an additional worldwide, exclusive license to use Cell-in-a-Boxlive cell encapsulation with cannabinoids to treat diseases and related symptoms and to tour the new facilities of Austrianova in Singapore. Mr. Waggoner and Dr. Crabtree will also be attending the grand opening of the cGMP (current Good Manufacturing Practices) facility in Thailand where the cells required for Nuvilex's preclinical and clinical trials will be encapsulated using the Cell-in-a-Box technology.
Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation
GlobeNewswire - Wed Nov 19, 9:33AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.
Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment
GlobeNewswire - Fri Nov 07, 8:35AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.
Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
Marketwired - Mon Nov 03, 9:49AM CST
Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be commercialized by US company Nuvilex, Inc. (OTCQB: NVLX) and its subsidiaries Nuvilex Australia and Nuvilex Europe.
Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
Marketwired - Wed Oct 29, 7:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research. The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex's Cell-in-a-Box® cellulose-based live cell encapsulation technology.
Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc.
PR Newswire - Wed Oct 22, 6:30AM CDT
Nuvilex, Inc. (OTCQB: NVLX) - According to the International Diabetes Federation, approximately 400 million people worldwide are living with diabetes, with that number expected to grow to 552 million people by 2030. The global market for diabetes treatments is approximately $500 billion.
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
Marketwired - Tue Oct 21, 8:10AM CDT
Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology. It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes. This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.
Nuvilex Contracts With University of Veterinary Medicine in Vienna to Conduct Preclinical Studies on the Use of Cell-in-a Box(R) to Develop Diabetes Treatment
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the University to perform "in vitro" and animal studies that use the Cell-in-a-Box cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has been granted worldwide, royalty-free, rights to use the results of the research conducted by the University for all commercial purposes.
Nuvilex files for shelf offering
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 3:17PM CDT
Nuvilex targeted chemo an Orphan Drug for pancreatic cancer
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:02AM CST
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment
GlobeNewswire - Mon Dec 22, 7:40AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex's pancreatic cancer treatment combines Nuvilex's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials.
Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation in New Facility
GlobeNewswire - Thu Dec 18, 11:56AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova's new facility in the Thai Science Park in Bangkok, Thailand. This is an important milestone in assuring the facility is compliant with the current Good Manufacturing Practices (cGMP) and that the encapsulation of the cancer prodrug-activating cells used in the Cell-in-a-Box technology platform, as part of Nuvilex's pancreatic cancer treatment, will be fully functional.
Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs
GlobeNewswire - Tue Dec 16, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box cellulose-based live cell encapsulation technology.
Nuvilex Provides Update on Significance of Austrianova's cGMP Live-Cell Encapsulation Facility
GlobeNewswire - Wed Dec 10, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park (TSP). This facility will produce the Cell-in-a-Box live-cell encapsulation product that will be the centerpiece for all of Nuvilex's treatments in human clinical trials.
Nuvilex Announces Name Change of Subsidiary to Viridis Biotech
GlobeNewswire - Mon Dec 08, 9:15AM CST
Nuvilex, Inc. (OTCQB:NVLX), a preclinical and clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has changed the name of its subsidiary, Medical Marijuana Sciences, Inc., to Viridis Biotech, Inc. This name change is part of Nuvilex's continuing process to make changes at Nuvilex that better reflect its role as a biotechnology company and to strengthen the Nuvilex brand.
American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST
GWPH: 68.08 (+1.82), FULL: 4.76 (-0.01)
Nuvilex Announces the Opening of Austrianova's cGMP Live Cell Encapsulation Facility in Thailand
GlobeNewswire - Thu Dec 04, 8:44AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova's current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.
Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine
GlobeNewswire - Mon Dec 01, 8:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has obtained an exclusive worldwide license from Austrianova Singapore Pte Ltd to use the unique and proprietary Cell-in-a-Box cellulose-based live cell encapsulation technology in combination with compounds, known as cannabinoids, obtained from constituents of Cannabis for the development of disease treatments. Nuvilex's initial efforts will be directed toward developing treatments for deadly and difficult-to-treat forms of cancer.
Legal Marijuana Industry Outlook Positive As Advanced Technologies & Socially Acceptable Cannabis Products Lead to Increased Revenues
PR Newswire - Mon Nov 24, 9:57AM CST
Legal Marijuana & Cannabis Industry lean more toward heavily capitalized investors as Leading Technology & MMJ Manufacturers set sights on the Mainstream and becoming more socially acceptable. Major MMJ Companies in focus today are: Surna Inc. (OTC: SRNA), Medical Marijuana Inc. (OTC: MJNA), Hemp, Inc. (OTC: HEMP), Cannabis Science, Inc. (OTC: CBIS) and Nuvilex, Inc. (OTC: NVLX)
Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes
GlobeNewswire - Mon Nov 24, 7:30AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a "Diabetes Consortium" that will be tasked with the development of Nuvilex's treatment for insulin-dependent diabetes.
Nuvilex Executives in Southeast Asia to Further Advance Cell-in-a-Box Technology(R)
GlobeNewswire - Fri Nov 21, 8:36AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today Nuvilex's Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will develop a treatment for insulin dependent diabetes, to negotiate an additional worldwide, exclusive license to use Cell-in-a-Boxlive cell encapsulation with cannabinoids to treat diseases and related symptoms and to tour the new facilities of Austrianova in Singapore. Mr. Waggoner and Dr. Crabtree will also be attending the grand opening of the cGMP (current Good Manufacturing Practices) facility in Thailand where the cells required for Nuvilex's preclinical and clinical trials will be encapsulated using the Cell-in-a-Box technology.
Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation
GlobeNewswire - Wed Nov 19, 9:33AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.
Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment
GlobeNewswire - Fri Nov 07, 8:35AM CST
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.
Breakthrough Diabetes Research to Be Commercialized by US-Based Nuvilex, Inc.
Marketwired - Mon Nov 03, 9:49AM CST
Australian research that has produced a line of insulin producing cells that could eliminate the need for injections for Type 1 diabetics will be commercialized by US company Nuvilex, Inc. (OTCQB: NVLX) and its subsidiaries Nuvilex Australia and Nuvilex Europe.
Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
Marketwired - Wed Oct 29, 7:45AM CDT
Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research. The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex's Cell-in-a-Box® cellulose-based live cell encapsulation technology.
Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc.
PR Newswire - Wed Oct 22, 6:30AM CDT
Nuvilex, Inc. (OTCQB: NVLX) - According to the International Diabetes Federation, approximately 400 million people worldwide are living with diabetes, with that number expected to grow to 552 million people by 2030. The global market for diabetes treatments is approximately $500 billion.
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
Marketwired - Tue Oct 21, 8:10AM CDT
Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology. It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes. This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.
Nuvilex Contracts With University of Veterinary Medicine in Vienna to Conduct Preclinical Studies on the Use of Cell-in-a Box(R) to Develop Diabetes Treatment
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the University to perform "in vitro" and animal studies that use the Cell-in-a-Box cellulose-based live cell encapsulation technology to develop a new treatment for insulin-dependent diabetes. Nuvilex has been granted worldwide, royalty-free, rights to use the results of the research conducted by the University for all commercial purposes.
Nuvilex files for shelf offering
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 3:17PM CDT
